FABRAZYME 35 MG
AGALSIDASE BETA : 35 MG · DIN 02248966 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is FABRAZYME?
FABRAZYME 35 MG contains AGALSIDASE BETA : 35 MG. It is listed in the Health Canada Drug Product Database under DIN 02248966, held by SANOFI-AVENTIS CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 08-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FABRAZYME used for?
FABRAZYME (agalsidase beta) is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02248966 |
|---|---|
| Brand name | FABRAZYME |
| Generic / active ingredient | AGALSIDASE BETA : 35 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 35 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | A16AB04 AGALSIDASE BETA |
| AHFS class | 44:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Apr-2024 |
| Original market date | 2004-04-08 00:00:00 |
How is it stored and handled?
null
How is it supplied?
1, 5 and 10 vials per carton.
What can be used instead?
Other Canadian products sharing ATC code A16AB04 AGALSIDASE BETA. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FABRAZYME | 5 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02248965 |
Who else supplies AGALSIDASE BETA worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AGALSIDASE BETA appears in 30 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.